Upload
lediep
View
221
Download
0
Embed Size (px)
Citation preview
Presenter Name 1
Presenter Name 2
Presenter Name 3
Month DD, YYYY
Penny M. Heaton, MD
May 16, 2017
Introducing Gates Medical Research Institute
HIV-AIDS
LRI
Diarrhea
Malaria
TB
© Bill & Melinda Gates Foundation | 3
Two vaccines WHO PQ’ed but
nearly 50% of GAVI budget.
Solutions?
1. Multi-dose vials
2. More low-cost suppliers
3. Dose reduction
4. Alternate conjugation
strategies
Children <5 years Adults >65 years
Pneumococcal Conjugate Vaccine
4
130 COUNTRIES HAVE INTRODUCED PNEUMOCOCCAL CONJUGATE
VACCINES INCLUDING 57 GAVI COUNTRIES (2016)
IVAC VIEW-Hub and Gavi
(130)
POLIO ERADICATION IS WITHIN REACH 5 CASES SO FAR THIS YEAR VS. 12 IN SAME TIME FOR 2016
2014 2017 2018 2020 2019 2016 2015
tOPV-bOPV
Switch Last use
of bOPV Global
Certification
bOPV + 1 dose IPV in routine
immunization
IPV-2 doses
HIV-AIDS
LRI
Diarrhea
Malaria
TB How can we make the
same progress against other
diseases?
Bill and Melinda Gates Medical
Research Institute (Gates MRI)
GATES MRI: GUIDING PRINCIPLES – WORKING DRAFT
BELIEF
PURPOSE WHO WE ARE AND WHAT WE
ARE ABOUT
VISION THE WORLD WE WANT
TO SEE
OUR CONTRIBUTION HOW WE ARE UNIQUE
MISSIONS THE OUTCOMES THAT HELP US
ACHIEVE OUR VISION
OUR VALUES HOW WE WORK
ALL LIVES HAVE EQUAL VALUE
We are committed to saving lives by harnessing science and technology to combat diseases
in the poorest populations
Improved lives for the world’s poorest populations through novel drugs, biologics, vaccines
and diagnostics
Top talent, deploying
cutting-edge science
to age-old problems
An agile, fast-to-
decision approach
A cross-cutting view
of disease areas and
modalities
Integration of data to
inform decisions
Develop effective therapeutics,
vaccines and diagnostics for
focus disease areas
Achieve PST disease area
goals
Continuously learn from
successes and failures
Collaboration Innovation Urgency Rigor “Truth seeking”
and learning
© Bill & Melinda Gates Foundation | 10
A FULLY INTEGRATED, NON-PROFIT ORGANIZATION FOCUSED ON TRANSLATIONAL PRODUCT DEVELOPMENT
Focus: Development from preclinical
candidate selection to clinical proof of
concept
Modalities: drugs, vaccines, antibodies,
biomarkers, and combination products
Fit-for-purpose for complex targets with
product development challenges but high
potential for impact
“Learn the truth in the shortest time and
at the lowest cost possible”
Translational development Discovery / research
Late phase
development
GMRI
Target HTS2 Hit to
lead
Lead
opt. Pre-clinical Ph I / IIa Ph IIb/ III
Vaccines
Biomarkers/
Diagnostics2 Disease area
Small
molecules Biologics3
TB
HIV
Pneumonia
NTD
EDD
Malaria
Polio
MNCH-D
ITS
Family Planning
© Bill & Melinda Gates Foundation | 11
WE’RE IN THE DESIGN PHASE…
What will stay the same?
Our approach to product development
• Strive to maximize impact in the shortest amount of
time
• Use data to inform decisions and increase the
probability of success
• End-to-end planning
Disease
Strategy
Prioritize
Portfolio
Target
Outcomes
Generate Data
Program
Strategy
Product
Development Modeling/ Quant.
Sciences
Integrated Planning
Monitor
Progress
Go/ No-
Go Go/ No-
Go
What will be different?
Can we close the gap between new
discoveries and application to our most
difficult diseases?
0%
20%
40%
60%
80%
100%
0 2 4 6 81012141618202224
Perc
enta
ge o
f countr
ies t
hat
have
u
niv
ers
ally
intr
oduced v
accin
e
Years since first introduction
Hib High-income country
Hib Low-income country
12 © Bill & Melinda Gates Foundation |
We are at the beginning of a multi-phase journey
Conceptual design Operational design
▪ Mission / vision /
objectives for GMRI
▪ Scope and key
capabilities required at
GMRI
▪ “Rules of engagement”
between GMRI and
BMGF and external
stakeholders
▪ Initial portfolio
▪ Detailed requirements
by function (resourcing,
infrastructure, etc)
▪ Alignment on decision-
making rights / RACIs
▪ Recruitment plan and
HR strategy
▪ Plan for Business
Operations support
Establishment
▪ Top leadership hires
▪ Infrastructure
▪ Key processes and
compliance established
▪ Executed agreements
with upstream partners
for portfolio assets
Execution on initial
focus areas
▪ Development of initial
portfolio
▪ Pipeline assets
transferred at
appropriate milestones
Expansion and
refinement
▪ Pipeline growth
▪ Additional focus areas
(disease, modality)
▪ Additional capabilities
Today Operations begin
Mid April – End July
Stay tuned…
…and thank you!